Search
                    Colorectal Neoplasms Clinical Trials
A listing of 26  Colorectal Neoplasms  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 26
        
                There are currently 26 active clinical trials seeking participants for Colorectal Neoplasms research studies. The states with the highest number of trials for Colorectal Neoplasms participants are California, Texas, Ohio and Florida.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    A Study of LY4257496 in Participants With Cancer (OMNIRAY)
                                
            
            
        Recruiting
                            
            
                The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced breast, colorectal, prostate, and endometrial cancer. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/20/2025
            
            Locations: University of California, Los Angeles (UCLA), Los Angeles, California  +10 locations         
        
        
            Conditions: Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis
        
            
        
    
                
                                    A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.
This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that:
* are advanced (cancer that doesn't disappear or stay away with treatment) and
* have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to gro...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2025
            
            Locations: Highlands Oncology Group, PA, Fayetteville, Arkansas  +24 locations         
        
        
            Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
        
            
        
    
                
                                    A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
                                
            
            
        Recruiting
                            
            
                This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresect...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2025
            
            Locations: Palo Verde Hematology Oncology, Glendale, Arizona  +388 locations         
        
        
            Conditions: Colorectal Neoplasms
        
            
        
    
                
                                    A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
This study also aims to find the best amount of study medication.
This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that:
* are advanced (cancer that doesn't disappear or stay away with treatment) a...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2025
            
            Locations: Highlands Oncology Group, Fayetteville, Arkansas  +11 locations         
        
        
            Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
        
            
        
    
                
                                    A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
                                
            
            
        Recruiting
                            
            
                This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.
Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic).
This study will have three parts. Parts A and B of the study will find out how much PF-08046052/SGN-EGFRd2 should be given to participants....  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2025
            
            Locations: Ronald Reagan UCLA Medical Center, Los Angeles, California  +22 locations         
        
        
            Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
        
            
        
    
                
                                    A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
                                
            
            
        Recruiting
                            
            
                This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2025
            
            Locations: Mayo Clinic Hospital, Phoenix, Arizona  +26 locations         
        
        
            Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
        
            
        
    
                
                                    A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma R...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/13/2025
            
            Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona  +221 locations         
        
        
            Conditions: Colorectal Neoplasms
        
            
        
    
                
                                    Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
                                
            
            
        Recruiting
                            
            
                Background:
Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant organs.
Objective:
To find a safe dose of metarrestin and to see if this dose shrinks tumors.
Eligibility:
Adults age 18 and older with pancreatic cancer, breast cancer, or a sol...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 12 years and 120 years
            Trial Updated:
                08/09/2025
            
            Locations: University of Kansas, Fairway, Kansas  +1 locations         
        
        
            Conditions: Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
        
            
        
    
                
                                    A Study of SGN-MesoC2 in Advanced Solid Tumors
                                
            
            
        Recruiting
                            
            
                This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/08/2025
            
            Locations: University of Alabama at Birmingham, Birmingham, Alabama  +23 locations         
        
        
            Conditions: Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
        
            
        
    
                
                                    First in Human Study of AZD9592 in Solid Tumors
                                
            
            
        Recruiting
                            
            
                This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/06/2025
            
            Locations: Research Site, Duarte, California  +49 locations         
        
        
            Conditions: Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
        
            
        
    
                
                                    A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/05/2025
            
            Locations: Florida Cancer Specialists, Sarasota, Florida  +1 locations         
        
        
            Conditions: Colorectal Neoplasms
        
            
        
    
                
                                    My Best GI Eating Study
                                
            
            
        Recruiting
                            
            
                The MyBestGI study evaluates three different approaches that could help people eat in healthier ways. The study seeks to enroll 240 overweight and obese persons who have risk factors for colorectal cancers such as a family or personal history of colorectal cancers or adenomatous polyps. The study website is www.MyBestGI.org .
Participants in the study will be asked to follow one of three eating plans, as best they can, for 12 months. Study participants can choose the foods they prefer within he...  Read More             
        
        
    Gender:
                ALL
            Ages:
                19 years and above
            Trial Updated:
                07/18/2025
            
            Locations: University of Michigan, Ann Arbor, Michigan         
        
        
            Conditions: Colorectal Neoplasms
        
            
        
    1 - 12 of 26
            